Drugs / AdVTMM2/DC Vaccination
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01622933 | Jun 2012 → May 2016 | melanoma | Lisa H. Butterfield, Ph.D. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdVTMM2/DC Vaccination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01622933 ↗ |
| Modality | Vaccine | “The investigational vaccine will be made with genes that are specific to melanoma” NCT01622933 ↗ |